GEETA, GEETA
GEETA, GEETA
DIPARTIMENTO DI MEDICINA E CHIRURGIA (SCHOOL OF MEDICINE AND SURGERY)
New pan-ALK inhibitor-resistant EML4::ALK mutations detected by liquid biopsy in lung cancer patients
2024 Villa, M; Malighetti, F; Sala, E; Sharma, G; Arosio, G; Gemelli, M; Manfroni, C; Fontana, D; Cordani, N; Meneveri, R; Zambon, A; Piazza, R; Pagni, F; Cortinovis, D; Mologni, L
Recurrent somatic mutations of FAT family cadherins induce an aggressive phenotype and poor prognosis in anaplastic large cell lymphoma
2024 Villa, M; Geeta, G; Malighetti, F; Mauri, M; Arosio, G; Cordani, N; Lobello, C; Larose, H; Pirola, A; D'Aliberti, D; Massimino, L; Criscuolo, L; Pagani, L; Chinello, C; Mastini, C; Fontana, D; Bombelli, S; Meneveri, R; Lovisa, F; Mussolin, L; Janikova, A; Pospíšilová, Š; Turner, S; Inghirami, G; Magni, F; Urso, M; Pagni, F; Ramazzotti, D; Piazza, R; Chiarle, R; Gambacorti-Passerini, C; Mologni, L
New advances in liquid biopsy technologies for anaplastic lymphoma kinase (Alk)—positive cancer
2021 Villa, M; Sharma, G; Manfroni, C; Cortinovis, D; Mologni, L
STAT3 and TP53 mutations associate with poor prognosis in anaplastic large cell lymphoma
2021 Lobello, C; Tichy, B; Bystry, V; Radova, L; Filip, D; Mraz, M; Montes-Mojarro, I; Prokoph, N; Larose, H; Liang, H; Sharma, G; Mologni, L; Belada, D; Kamaradova, K; Fend, F; Gambacorti Passerini, C; Merkel, O; Turner, S; Janikova, A; Pospisilova, S
Synergistic drug combinations prevent resistance in ALK+ anaplastic large cell lymphoma
2021 Arosio, G; Sharma, G; Villa, M; Mauri, M; Crespiatico, I; Fontana, D; Manfroni, C; Mastini, C; Zappa, M; Magistroni, V; Ceccon, M; Redaelli, S; Massimino, L; Garbin, A; Lovisa, F; Mussolin, L; Piazza, R; Gambacorti Passerini, C; Mologni, L
IL10RA modulates crizotinib sensitivity in NPM1-ALK+ anaplastic large cell lymphoma
2020 Prokoph, N; Probst, N; Lee, L; Monahan, J; Matthews, J; Liang, H; Bahnsen, K; Montes-Mojarro, I; Karaca-Atabay, E; Sharma, G; Malik, V; Larose, H; Forde, S; Ducray, S; Lobello, C; Wang, Q; Luan, S; Pospisilova, S; Gambacorti Passerini, C; Burke, G; Pervez, S; Attarbaschi, A; Janikova, A; Pacquement, H; Landman-Parker, J; Lambilliotte, A; Schleiermacher, G; Klapper, W; Jauch, R; Woessmann, W; Vassal, G; Kenner, L; Merkel, O; Mologni, L; Chiarle, R; Brugieres, L; Geoerger, B; Barbieri, I; Turner, S
Phase two study of crizotinib in patients with anaplastic lymphoma kinase (ALK) positive anaplastic large cell lymphoma relapsed/refractory to chemotherapy
2020 Bossi, E; Aroldi, A; Brioschi, F; Steidl, C; Baretta, S; Renso, R; Verga, L; Fontana, D; Sharma, G; Mologni, L; Mussolin, L; Piazza, R; Gambacorti Passerini, C
A Compound L1196M/G1202R ALK Mutation in a Patient with ALK-Positive Lung Cancer with Acquired Resistance to Brigatinib Also Confers Primary Resistance to Lorlatinib
2019 Sharma, G; Cortinovis, D; Agustoni, F; Arosio, G; Villa, M; Cordani, N; Bidoli, P; Bisson, W; Pagni, F; Piazza, R; Gambacorti-Passerini, C; Mologni, L
In vitro and in vivo characterization of resistance to lorlatinib treatment in ALK mutated cancers
2019 Geeta, G
Phase ii study with crizotinib in patients with anaplastic lymphoma kinase (alk)-positive lymphoma relapsed/refractory to chemotherapy
2019 Bossi, E; Brioschi, F; Steidl, C; Baretta, S; Cantu, S; Verga, L; Fontana, D; Sharma, G; Mologni, L; Mussolin, L; Piazza, R; Gambacorti Passerini, C
We shall overcome (drug resistance) some day
2019 Geeta, G; Mologni, L
Wiskott–Aldrich syndrome protein (WASP) is a tumor suppressor in T cell lymphoma
2019 Menotti, M; Ambrogio, C; Cheong, T; Pighi, C; Mota, I; Cassel, S; Compagno, M; Wang, Q; Dall’Olio, R; Minero, V; Poggio, T; Geeta, G; Patrucco, E; Mastini, C; Choudhari, R; Pich, A; Zamo, A; Piva, R; Giliani, S; Mologni, L; Collings, C; Kadoch, C; Gambacorti-Passerini, C; Notarangelo, L; Anton, I; Voena, C; Chiarle, R
Abstract 902: In vitro andin vivocharacterization of resistance to lorlatinib treatment in ALK mutated cancers
2018 Geeta, G; Redaelli, S; Ceccon, M; Zappa, M; Gambacorti-Passerini, C; Mologni, L
Concomitant BCORL1 and BRAF Mutations in Vemurafenib-Resistant Melanoma Cells
2018 Mologni, L; Costanza, M; Sharma, G; Viltadi, M; Massimino, L; Citterio, S; Purgante, S; Raman, H; Pirola, A; Zucchetti, M; Piazza, R; Gambacorti-Passerini, C
Lorlatinib treatment elicits multiple on- and off-target mechanisms of resistance in ALK-driven cancer
2018 Redaelli, S; Ceccon, M; Zappa, M; Geeta, G; Mastini, C; Mauri, M; Nigoghossian, M; Massimino, L; Cordani, N; Farina, F; Piazza, R; Gambacorti-Passerini, C; Mologni, L
Tumor Resistance against ALK Targeted Therapy-Where It Comes From and Where It Goes
2018 Sharma, G; Mota, I; Mologni, L; Patrucco, E; Gambacorti-Passerini, C; Chiarle, R
Long-term efficacy and safety of crizotinib in relapsed ALK positive lymphoma patients: clinical and biological correlates
2017 Farina, F; Ceccon, M; Mori, S; Verga, L; Borin, L; Mologni, L; Fontana, D; Geeta, G; Piazza, R; Gambacorti-Passerini, C